Study On Immune Response To Double-Expressing HBV-S DNA Vaccine

Aim: Hepatitis B virus (HBV) remains an important world wide health problem. At present, the most effective measure to prevent and control HBV is to inoculate hepatitis B vaccines. Due to poor immunogenicity, common hepatitis B vaccines are incorporated aluminium adjuvant to enhance humoral immunity, but aluminium adjuvant inhibits cell immunity. Common hepatitis B vaccines only produce prevention rather than therapy. Even we inoculate vaccine according to current standard procedure, about 5%-10% of inoculator could not have positive antibody. Because of poor immunogenicity and other factors, HBV DNA vaccine which has both preventative and therapeutical effect can be difficult to apply in clinics. Our experiment is to construct two copies target genes in one vector to increase amont of antien, and enhance immune response to HBsAg.Method: Target gene S1 and S2 were amplified with PCR, and subcloned into plasmid pMD18-TS respectively, namely pMD18-TS-S1 and pMD18-TS-S2, which were used to sequence. Fragment S1 from pMD18-TS-S1 and S2 from pMD18-TS-S2 were inserted into plasmid...